More recently, a lutetium-177-labeled small molecule targeting prostate membrane specific antigen (PSMA-617) has been developed, with the goal of delivering radiation therapy more specifically to all sites of metastatic disease. The gene discussed is FOLH1; the disease is metastatic neoplasm.